Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship

被引：1
|
作者：
Rubboli, Andrea [1 ]
Verheugt, Freek W. A. [2 ]
机构：
[1] Osped Maggiore Bologna, Lab Intervent Cardiol, Div Cardiol, Largo Nigrisoli 2, I-40133 Bologna, Italy
[2] OLVG, Heartctr, Dept Cardiol, Oosterpk 9, NL-1091 AC Amsterdam, Netherlands
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2016年 / 223卷
关键词：
Non-vitamin K-antagonist oral anticoagulants; Oral anticoagulation; ATRIAL-FIBRILLATION; RENAL-FUNCTION; WARFARIN; RIVAROXABAN; DABIGATRAN; APIXABAN; EFFICACY; SAFETY;
D O I：
10.1016/j.ijcard.2016.08.207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：519 / 520
页数：2
相关论文
共 50 条
  • [1] Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
    Plitt, Anna
    Ruff, Christian T.
    Giugliano, Robert P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1019 - +
  • [2] Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation
    Jelonek, Olga
    Gorczyca, Iwona
    Baczek, Michal
    Kosmider, Pawel
    Wozakowska-Kaplon, Beata
    KARDIOLOGIA POLSKA, 2018, 76 (07) : 1073 - 1080
  • [3] Comparison of non-vitamin K antagonist oral anticoagulants on bleeding and thrombosis
    Liu, Zhiyan
    Ma, Lingyue
    Zhang, Hanxu
    Mu, Guangyan
    Xie, Qiufen
    Zhou, Shuang
    Wang, Zining
    Wang, Zhe
    Hu, Kun
    Gong, Yanjun
    Jiang, Jie
    Xiang, Qian
    Cui, Yimin
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (06) : 1729 - 1742
  • [4] Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
    Malagu, Michele
    Longo, Filomena
    Marchini, Federico
    Sirugo, Paolo
    Capanni, Andrea
    Clo, Stefano
    Mari, Elisa
    Culcasi, Martina
    Bertini, Matteo
    BIOLOGY-BASEL, 2023, 12 (04):
  • [5] Non-Vitamin K Antagonist Oral Anticoagulants in Pulmonary Embolism: An Overview of Systematic Reviews
    Doundoulakis, Ioannis
    Antza, Christina
    Karvounis, Haralambos
    Giannakoulas, George
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (23) : 2686 - 2691
  • [6] Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation
    Santarpia, Giuseppe
    Curcio, Antonio
    Sibilio, Gerolamo
    Indolfi, Ciro
    CIRCULATION JOURNAL, 2015, 79 (05) : 914 - 923
  • [7] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [8] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [9] Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials
    Wang, Kang-Ling
    Lopes, Renato D.
    Patel, Manesh R.
    Buller, Harry R.
    Tan, Doreen Su-Yin
    Chiang, Chern-En
    Giugliano, Robert P.
    EUROPEAN HEART JOURNAL, 2019, 40 (19) : 1492 - 1500
  • [10] Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know
    Amin, Alpesh
    OCHSNER JOURNAL, 2016, 16 (04) : 531 - 541
12345